Vedanta Biosciences

Vedanta Biosciences is a leader in the microbiome therapeutics space, advancing a pipeline of orally administered, defined bacterial consortia for gastrointestinal diseases. Its most advanced candidate, VE303, is in Phase 3 development for the prevention of recurrent C. difficile infection, with Phase 2 data recently published in *Nature Medicine*. The company's differentiated approach involves selecting specific bacterial strains to target the underlying microbial, metabolic, and immunologic imbalances of disease, positioning it to address significant unmet needs in areas like IBD and recurrent infections.

Proprietary platform for the discovery and rational design of defined consortia of human commensal bacteria, manufactured from clonal cell banks, for use as oral Live Biotherapeutic Products (LBPs).

Vedanta competes in the microbiome therapeutics space against companies developing fecal microbiota transplants (FMT), single-strain probiotics, and other consortium approaches. Its key differentiation is the rational design and pharmaceutical-grade manufacturing of defined bacterial consortia. In rCDI, competitors include Seres Therapeutics (commercial product SER-109) and Finch Therapeutics, while in IBD, the competitive field is broader and includes large pharma companies with biologic drugs.